https://doi.org/10.1038/s41416-022-02061-5
I
Ioannis Karfis
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
44
Papers
534
Citations
13
h-index
14
i10-index
Ioannis Karfis is an academic researcher from Institut Jules Bordet. The author has contributed to research in topics: Neuroendocrine Tumor Research Advances & Lung Cancer Research Studies & Neuroblastoma Research and Treatments. The author has an h-index of 13, co-authored 38 publications.
ORCID: 0000-0003-2158-3981Papers by this author
worksDual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
2022 · British Journal of Cancer · 76 citations
177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors
2024 · Clinical Nuclear Medicine · 8 citations
https://doi.org/10.1097/rlu.0000000000005330
[177Lu]Lu-PSMA SPECT/CT for early response assessment using quantitative RECIP 1.0
2025 · European Journal of Nuclear Medicine and Molecular Imaging · 3 citations
https://doi.org/10.1007/s00259-025-07613-4
Phosphaturic mesenchymal tumor demonstrated by 68Ga-DOTATATE PET/CT in a patient: a case report
2024 · EJNMMI Reports · 2 citations
https://doi.org/10.1186/s41824-024-00219-3
First-in-human experience of radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in patients with advanced multiple myeloma
2025 · EJNMMI Reports · 0 citations
https://doi.org/10.1186/s41824-025-00262-8
VERLen: Tafasitamab, Lenalidomide, plus Rituximab in Frontline Diffuse Large B-cell Lymphoma Patients over 80 Y/O or Older, A LYSA Phase 2 trial
2025 · DIAL (Catholic University of Leuven) · 0 citations
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat